Sign in
CompletedNo phase

Feasibility Study of the Tendyne Mitral Valve System in Mitral Annular Calcification

Key facts

Who runs it
Abbott Medical Devices
Where
Atlanta, Minneapolis, Morgantown, and Wichita, United StatesSee the 4 sites
Trial code
Status
Completed
People taking part
11 people enrolled
Started
10 Oct 2018
Ended
18 Jun 2024
Type of study
Interventional
Treatments tested
  • Tendyne Mitral Valve System
Record updated
18 November 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 36 criteriaShow less

Who can take part

  • Heart Team determines subject is not a suitable candidate for conventional surgical treatment due to degree of MAC present and the subject will likely benefit from transcatheter valve implantation
  • Symptomatic, severe mitral regurgitation, as defined in the 2017 ACC expert Consensus Decision Pathway on the Management of MR
  • NYHA Functional Classification ≥ II (if Class IV, patient must be ambulatory)
  • Age 18 years or older at time of consent
  • Not a member of a vulnerable population per the investigator's judgment
  • The subject or the subject's legal representative has been informed of the nature of the study and agrees to its provisions, including complying with study required testing and follow-up visits, and has provided written informed consent

Who cannot take part

  • Severe mitral stenosis not amenable to balloon valvuloplasty or transcatheter therapy
  • Prior intervention with permanently implanted mitral device (e.g. MitraClip)
  • Any planned cardiac surgery or intervention that is 30 days prior and 30 days post that is not concomitant with the Tendyne procedure
  • Cerebrovascular accident (CVA) within six months of planned implant procedure
  • Cardiogenic shock or hemodynamic instability requiring inotropes or mechanical support devices within 1 month prior to planned implant procedure
  • Subject has COPD requiring continuous home oxygen therapy or chronic outpatient oral steroid use
  • Currently participating in an investigational drug or another device trial that has not reached its primary endpoint
  • Chest condition that prevents transapical access
  • Cardiac resynchronization therapy (CRT) device or implantable pulse generator (IPG) implanted within three months of planned implant procedure
  • Myocardial Infarction (MI) within 30 days of the planned implant procedure
  • Symptomatic, or ischemia-associated coronary artery disease (e.g., active ischemia) amenable to revascularization and thus requiring stenting or CABG
  • Hypertrophic or restrictive cardiomyopathy, constrictive pericarditis or any other structural heart disease causing heart failure other than dilated cardiomyopathy of either ischemic or non-ischemic etiology
  • Any of the following: leukopenia, acute anemia, thrombocytopenia, history of bleeding diathesis, or coagulopathy if cannot be adequately treated
  • History of endocarditis within 6 months of planned implant procedure
  • Active systemic infection requiring antibiotic therapy
  • Known hypersensitivity or contraindication to procedural or post-procedural medications (e.g., contrast solution, anti-coagulation therapy) which cannot be adequately managed medically
  • Known hypersensitivity to nickel or titanium
  • Subject is undergoing hemodialysis due to chronic renal failure ( ≥ Stage 4 CKD)
  • Subject has pulmonary arterial hypertension (fixed PAS >70mmHg)
  • Subjects with non-cardiac co-morbidities that are likely to result in a life expectancy of less than 12 months
  • Left Ventricular Ejection Fraction (LVEF) less than 25% assessed by echocardiogram
  • Presence of Left Ventricle or Left Atrium thrombus
  • Left Ventricular End Diastolic Dimension (LVEDD) > 7.0 cm
  • Mitral pathoanatomy and Left Ventricular Outflow tract (LVOT) anatomy deemed not suitable for Tendyne mitral valve implantation
  • Unresolved severe symptomatic carotid stenosis (> 70% by ultrasound)
  • Severe tricuspid regurgitation or severe right ventricular dysfunction
  • Subject unable or unwilling to take anticoagulation with warfarin for a minimum of 6 months following Tendyne valve implantation
  • FEV1 < 50% of predicted or < 1L
  • Subject refuses blood transfusions
  • Pregnant, lactating, or planning pregnancy within next 12 months

Where in United States

  • Emory University HospitalAtlanta, United States
  • Abbott-Northwestern HospitalMinneapolis, United States
  • West Virginia UniversityMorgantown, United States
  • Cardiovascular Research Institute of KansasWichita, United States

About the trial

What the trial wants to find out

This study is a prospective, single-arm, multi-center feasibility clinical study of the Tendyne Mitral Valve System for the treatment of eligible subjects with symptomatic, severe mitral regurgitation and severe mitral annular calcification (MAC). Subjects satisfying the study inclusion/exclusion criteria will undergo a procedure to implant the Tendyne mitral valve replacement device.

The group in the trial

  • Device ArmTreatment being tested

    All subjects will undergo procedure with the Tendyne Mitral Valve System.

    Treatment: Tendyne Mitral Valve System

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Feasibility Study of the Tendyne Mitral Valve System for Use in Subjects With Mitral Annular Calcification
Record updated
18 November 2024